Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 8/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.43 |
| ▸ | UMPS | P11172 | 4/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.41 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19370845 | 0.91 | FBP1 (0.50) | P2RY2P2RY6UMPSDNPH1 | |
| SCHEMBL1364683 | 0.91 | FBP1 (0.50) | P2RY2P2RY6UMPSDNPH1 | |
| SCHEMBL7269691 | 0.91 | FBP1 (0.50) | P2RY2P2RY6UMPSDNPH1 | |
| SCHEMBL21067752 | 0.73 | NT5E (0.30) | — | |
| SCHEMBL11178912 | 0.70 | HPRT1 (0.53) | P2RY2P2RY6UMPSDNPH1 | |
| SCHEMBL13828785 | 0.69 | FBP1 (0.56) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL10295498 | 0.69 | FBP1 (0.56) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL24989466 | 0.69 | P2RY2 (0.81) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL26202447 | 0.69 | P2RY2 (0.81) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL26573652 | 0.68 | P2RY6 (0.42) | P2RY2P2RY6P2RY4UMPSP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | P2RY2 3144/4885P2RY6 3186/4885P2RY4 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.